Fosamax and Osteonecrosis of the Jaw: A Clinical Evidence Review of Causation

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Targeted Risk Assessment

The legacy context of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad framework, discussions of bone health and osteoporosis management have been common, often focusing on lifestyle factors and therapeutic interventions. As audiences become more informed, there is a natural progression from general health awareness to specific inquiries about medication-related risks. This transition is particularly relevant when considering bisphosphonate therapies, such as Fosamax, which have been widely prescribed for osteoporosis. The shift from general health discourse to a more focused examination of adverse effects reflects an evolving public health concern. Specifically, the association between Fosamax exposure and osteonecrosis of the jaw has emerged as a topic requiring careful clinical review. This pivot moves beyond general health education into a targeted assessment of risk factors, exposure duration, and patient populations. The occupational exposure dimension becomes pertinent when considering healthcare professionals, dental practitioners, and patients who may encounter this medication in clinical settings. Understanding the transition from broad health information to specific risk evaluation is essential for developing appropriate screening and monitoring protocols. This progression underscores the importance of translating general health knowledge into actionable clinical insights regarding medication safety and patient outcomes.

Bridging General Awareness to Clinical Evidence

Building on the foundation of general health education, this section transitions to a detailed clinical examination of Fosamax (alendronate sodium) and its association with osteonecrosis of the jaw (ONJ). Fosamax is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Its clinical utility in reducing fracture risk is well established, but its use has been associated with a serious adverse effect: osteonecrosis of the jaw. This condition is characterized by exposed, non-healing bone in the maxillofacial region, often accompanied by pain, swelling, infection, or drainage. Diagnosis is based on clinical examination and imaging, with a focus on ruling out other causes such as metastatic disease or radiation-induced osteonecrosis. The condition can occur spontaneously but is generally associated with tooth extraction, local infection, or delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Multiscale characterization of jawbone tissue has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/).

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Fosamax to ONJ are not fully elucidated but are believed to involve the drug's potent inhibition of osteoclast-mediated bone resorption. Bisphosphonates like alendronate accumulate in bone, particularly in areas of high turnover such as the jaw, and suppress remodeling. This suppression can impair the ability of bone to repair microdamage and respond to local stressors, such as dental procedures or infection. The resulting avascular necrosis is thought to arise from a combination of reduced bone turnover, compromised blood supply, and local inflammation. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders (e.g., periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, ill-fitting dentures) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The timeline between exposure to Fosamax and documented harm varies widely. The time to onset of symptoms has been reported to range from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, ONJ is more commonly associated with longer-term use, and the risk may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). In placebo-controlled clinical studies of Fosamax, the percentages of patients with symptoms such as bone pain or jaw issues were similar in the Fosamax and placebo groups, suggesting that early symptoms may not be specific to ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients who developed severe symptoms had relief after stopping the drug, but a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

Warnings, Risk-Benefit Assessment, and Causation Considerations

From a risk perspective, the adequacy of warnings regarding Fosamax and ONJ is addressed in the drug's prescribing information. The label includes a specific warning under Section 5.4, "Osteonecrosis of the Jaw," which states that ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The label also notes that for patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). However, the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). This suggests that while warnings exist, the risk-benefit assessment for long-term use remains an area of clinical consideration. For affected patients, causation-related considerations involve evaluating the temporal relationship between Fosamax exposure and the development of ONJ, as well as the presence of other risk factors. The label acknowledges that ONJ can occur spontaneously, but it is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Therefore, establishing causation in individual cases requires careful documentation of exposure duration, dental history, and other contributing factors. The variability in onset—from days to months—complicates the determination of a clear causal link, but the recurrence of symptoms upon rechallenge provides supportive evidence for a drug-related effect (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In summary, the clinical evidence supports a recognized association between Fosamax use and osteonecrosis of the jaw, with mechanistic plausibility involving suppressed bone remodeling. The risk is influenced by duration of use, dental procedures, and other comorbidities. Warnings in the prescribing information are present but may require careful interpretation in the context of individual patient risk factors and the variable timeline of harm.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it related to osteonecrosis of the jaw?

Fosamax (alendronate sodium) is a bisphosphonate used to treat osteoporosis. It has been associated with osteonecrosis of the jaw (ONJ), a condition where jawbone tissue dies and becomes exposed. The risk is higher with long-term use and dental procedures. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

What are the risk factors for developing ONJ while taking Fosamax?

Risk factors include invasive dental procedures (e.g., tooth extraction, implants), cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids), poor oral hygiene, and comorbidities like periodontal disease or anemia. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1)

How long does it take for Fosamax to cause osteonecrosis of the jaw?

Onset can vary from one day to several months after starting the drug, but ONJ is more common with longer-term use. The risk increases with duration of exposure. (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56)

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.